Aim To explore the putative association of new-onset diabetes and the soluble urokinase plasminogen activator receptor (suPAR), which is a new and stable plasma marker of immune function and low-grade inflammation. This association has been previously suggested by using the less sensitive International Classification of Disease system to detect incident diabetes in the Danish MONICA10 cohort. Methods The Danish National Diabetes Register enabled more accurate identification of incident diabetes during a median follow-up of 13.8years in the Danish MONICA10 cohort (n=2353 generally healthy individuals). The soluble urokinase plasminogen activator receptor was measured by the ELISA method. To fulfil model assumptions, outcome analyses were stratified by age, and further by smoking, owing to the interaction between the soluble urokinase plasminogen activator receptor and smoking on new-onset diabetes (P<0.0001). Results New-onset diabetes (n=182) was associated with increased soluble urokinase plasminogen activator receptor levels (P=0.013). Among 699 middle-aged (41 and 51years) and 564 older (61 and 71years) non-smokers, participants in the upper soluble urokinase plasminogen activator receptor quartile had a sex- and age-adjusted relative risk of 6.01 (95%CI 2.17-16.6, P<0.0006) and relative risk of 3.25 (95%CI 1.51-6.98, P=0.0025), respectively, for new-onset diabetes compared with participants in the lowest quartile. This relationship remained significant after additional adjustments for C-reactive protein and leukocytes or fasting glucose and insulin or BMI (P<0.05). The soluble urokinase plasminogen activator receptor was not related to incident diabetes among smokers (P≥0.85). Conclusions In these explorative analyses, the soluble urokinase plasminogen activator receptor associated independently with incident diabetes in non-smokers, supporting an immune origin of Type2 diabetes. Competing disease risk may explain lack of association among smokers.
|Status||Udgivet - 1 apr. 2012|